Full video transcriptClick to expand
Auto-generated transcript of @ahmadyasinmd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00This is the strongest weight loss peptide in the market now. This is RateroTide. My name is Dr.
- 0:05Yasin. I talk peptides, bireglators and sums. I help you lose fat, gain lean muscle and be great
- 0:12in bed again. I'm going to talk about the third generation of GLP medications for weight loss.
- 0:18This is called RateroTide. Keep in mind that RateroTide until today, it's not approved by the F-Tine
- 0:25and it's still in phase 3. It works on three receptors, GLP1, GIP and GlucoGone to promote weight
- 0:32loss. It improves blood sugar control and enhances the top look out. It combines appetite suppression,
- 0:39increased energy expenditure and improved insulin sensitivity. And of course, it shows promises for
- 0:45managing obesity and type 2 diabetes. This is a very strong peptide and it does do wonders. I
- 0:52have also tried it and it's a game changer. What are the side effects? nausea, vomiting,
- 0:58appetite suppression, which is anticipated. Bire side effect including increased heart rate,
- 1:04dizziness and injection side reaction. What closing? Usually we start with 0.5 milligram weekly and then
- 1:11we go up. The maximum dose studied its 12 milligram per week. This video is only for educational
- 1:18purposes. Please do not buy, take any peptide before talking to your doctor. If you want to know
- 1:23more about the peptide world, please follow me and like the video and I'll see you in the next one.
- 1:27Thank you so much for watching.
Retatrutide for weight loss: what the phase 2 data actually shows
Quick answer
Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) currently in phase 3 trials with no FDA approval as of 2024. Phase 2 data showed up to 24.2% mean body weight reduction at 12 mg weekly (Jastreboff et al., 2023, NEJM), but glucagon receptor activity raises cardiac monitoring considerations not yet fully characterized in long-term data. No compounded or commercially available version has been evaluated by the FDA for safety, purity, or efficacy.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Retatrutide for weight loss: what the phase 2 data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Retatrutide for weight loss: what the phase 2 data actually shows should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Retatrutide for weight loss: what the phase 2 data actually shows" from Ahmad Yasin MD. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) currently in phase 3 trials with no FDA approval as of 2024.
The reason this review is not generic is the source wording and the canonical claim label "glp1 retarutide the most powerful weight loss peptide skinnytalk." In this clip, the useful excerpt is: "This is the strongest weight loss peptide in the market now." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) currently in phase 3 trials with no FDA approval as of 2024.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) currently in phase 3 trials with no FDA approval as of 2024. Phase 2 data showed up to 24.2% mean body weight reduction at 12 mg weekly (Jastreboff et al., 2023, NEJM), but glucagon receptor activity raises cardiac monitoring considerations not yet fully characterized in long-term data. No compounded or commercially available version has been evaluated by the FDA for safety, purity, or efficacy.
- Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24.2% mean body weight reduction with retatrutide 12 mg at 48 weeks, the highest reduction reported for any single agent in a controlled trial to date.
- Retatrutide is not FDA-approved and has no legally available commercial form. Any product sold outside a clinical trial is unapproved and unverified for purity or concentration.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24.2% mean body weight reduction with retatrutide 12 mg at 48 weeks, the highest reduction reported for any single agent in a controlled trial to date.
- Retatrutide is not FDA-approved and has no legally available commercial form. Any product sold outside a clinical trial is unapproved and unverified for purity or concentration.
- Glucagon receptor agonism, the feature that may drive superior fat loss, also increases resting heart rate. This cardiac signal has not been fully characterized in long-term outcome studies.
- Phase 3 TRIUMPH trials are ongoing as of 2024. Without phase 3 data and cardiovascular outcomes, efficacy and long-term safety claims remain preliminary.
- Tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy/Ozempic) are the currently approved options with large-scale trial data and real-world evidence supporting their use for weight management.
- Physician self-disclosure of personal use of unapproved investigational compounds on social media, regardless of educational intent, contributes to normalization of unsupervised access to unregulated peptides.
- Side effects specific to glucagon receptor activation, including increased heart rate and dizziness, are not typical of GLP-1 monotherapy and represent a distinct risk profile that warrants clinical monitoring.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @ahmadyasinmd actually say?
Dr. Yasin described retatrutide as "the strongest weight loss peptide in the market now" and called it a "third generation" GLP medication targeting three receptors: GLP-1, GIP, and glucagon. He noted it is not yet FDA-approved and still in phase 3 trials. He also disclosed that he personally tried it and called it "a game changer." That last part deserves immediate attention, because a physician self-administering an unapproved investigational compound and promoting it to 155,000 viewers is not a neutral educational act.
He named standard side effects, gave a dosing range starting at 0.5 mg weekly up to a studied maximum of 12 mg weekly, and closed with a disclaimer to consult a doctor before taking any peptide. The disclaimer is appreciated, but it does not fully offset the promotional framing throughout.
Does the science back this up?
On the pharmacology, he is largely correct. Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 data published by Jastreboff et al. (2023, NEJM) showed mean body weight reduction of up to 24.2% over 48 weeks at the 12 mg dose, which is genuinely impressive and exceeds what tirzepatide achieved in comparable trial durations.
The glucagon receptor component is the key differentiator. Unlike tirzepatide, which is a dual GLP-1/GIP agonist, retatrutide's glucagon activation appears to drive additional energy expenditure, not just appetite suppression. This is the mechanistic basis for the "stronger" claim, and it has real data behind it. However, "strongest in the market" is a stretch since it is not in the market. It is in trials. That distinction matters.
Phase 3 trials (the TRIUMPH program) are ongoing as of 2024. No long-term cardiovascular outcome data exist yet, which is a significant gap given the glucagon receptor activity and its known effects on heart rate.
What did they get wrong (or right)?
Credit where it is due: he correctly identified the three receptor targets, accurately stated FDA non-approval and phase 3 status, and named real documented side effects including increased heart rate and dizziness, which are specifically tied to glucagon receptor activation and are not common to standard GLP-1 drugs.
What he got wrong, or at least reckless: calling it "the strongest weight loss peptide in the market" when it is not in the market. That phrasing implies availability it does not have. Worse, disclosing personal use of an unapproved compound to a lay audience of over 150,000 people normalizes access to investigational drugs outside any clinical framework.
The dosing information, starting at 0.5 mg and going to 12 mg weekly, mirrors the Jastreboff 2023 phase 2 protocol. Sharing this on TikTok is not education. It is a dosing guide for people who will find compounded or gray-market versions online. That is a real harm vector regardless of intent.
What should you actually know?
Retatrutide is not available through any approved pharmacy. Period. What you can find online is either compounded retatrutide of unknown purity and concentration, or something mislabeled entirely. The FDA has not evaluated any of these products for safety or efficacy.
The phase 2 results from Jastreboff et al. are genuinely exciting to researchers and clinicians. A 24% average weight reduction in under a year would be clinically significant if it holds in phase 3 and if the cardiovascular safety profile is acceptable. We do not have that data yet.
Glucagon receptor agonism increases resting heart rate and can affect blood pressure. This is not a trivial side effect in a population that already carries elevated cardiovascular risk due to obesity. Anyone who reads about retatrutide's weight loss numbers without reading about its cardiac signals is getting half the story.
If you are interested in GLP-1 based therapies that are actually approved and available, semaglutide and tirzepatide have robust phase 3 and real-world data behind them. Those are conversations worth having with a licensed clinician on a regulated platform, not a TikTok comment section.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Ahmad Yasin MD · TikTok creator
155.5K views on this video
🎯 RETARUTIDE: The Most Powerful Weight Loss Peptide? 💉🔥 | #SkinnyTalk by Dr. Yasin @SKIN4U Med Spa Looking for the next breakthrough in weight loss peptides? Meet Retarutide — a third-generation GLP medication that targets GLP-1, GIP, and Glucagon receptors to deliver serious fat loss results. 🚀 Hi, I’m Dr. Ahmad Yasin, your go-to expert in peptides, SARMs, and bioregulators. At SKIN4U Med Spa (Commerce Township, MI), I help people lose fat, gain lean muscle, and optimize their health — all
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about phase 2 data (jastreboff et al., 2023, nejm) showed up?
Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24.2% mean body weight reduction with retatrutide 12 mg at 48 weeks, the highest reduction reported for any single agent in a controlled trial to date.
What does the video say about retatrutide?
Retatrutide is not FDA-approved and has no legally available commercial form. Any product sold outside a clinical trial is unapproved and unverified for purity or concentration.
What does the video say about glucagon receptor agonism, the feature?
Glucagon receptor agonism, the feature that may drive superior fat loss, also increases resting heart rate. This cardiac signal has not been fully characterized in long-term outcome studies.
What does the video say about phase 3 triumph trials?
Phase 3 TRIUMPH trials are ongoing as of 2024. Without phase 3 data and cardiovascular outcomes, efficacy and long-term safety claims remain preliminary.
What does the video say about tirzepatide (mounjaro/zepbound)?
Tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy/Ozempic) are the currently approved options with large-scale trial data and real-world evidence supporting their use for weight management.
What does the video say about physician self-disclosure of personal use of unapproved investigational compounds on?
Physician self-disclosure of personal use of unapproved investigational compounds on social media, regardless of educational intent, contributes to normalization of unsupervised access to unregulated peptides.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Ahmad Yasin MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.